News & Media

SK life science

Welcome to the news and information center for SK Life Science, Inc. (SKLSI), a CNS-focused pharmaceutical company





General business

Strategic alliance and partnership opportunities

Media inquiries and PR

Grant and investigator initiated proposals

Sponsorship requests

Medical information inquiries or report adverse events

SK life science at a glance

  • Headquarters location

    PARAMUS, NJ

  • R&D Begins

    1993

  • Parent Company

    SK life science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and both are part of the SK Group

  • Number of employees

    200+ EMPLOYEES

  • Disease Category Focus

    CNS

  • Pipeline

    8 compounds under clinical development

Newsroom

SK life science Receives Schedule V Designation from DEA for XCOPRI® (cenobamate tablets)

Full release

SK life science to Present Latest Cenobamate Data at the American Epilepsy Society 2019 Annual Meeting

Full release

SK Life Science, Inc. Announces FDA Acceptance of IND Application for Anti-Epileptic Drug Candidate SKL24741

Full release

FDA Approves XCOPRI® (cenobamate tablets) CV, an Anti-Epileptic Drug (AED) from SK Biopharmaceuticals, Co., Ltd., and U.S. Subsidiary SK Life Science, Inc.

Full release

Results of a Randomized Study of the Safety and Efficacy of Cenobamate in Adults with Uncontrolled Focal Seizures Published in The Lancet Neurology

Full release

New National Epilepsy Survey Reveals Significant Disconnects on Important Issues Among Patients, Caregivers and Healthcare Professionals

Full release

SK life science Expands Support for the J. Kiffin Penry Epilepsy Education Programs to Reach More Healthcare Providers

Full release

SK life science Provides Update on Recent Company Milestones and Accomplishments

Full release

SK life science to Showcase Scientific Data at the 2019 American Academy of Neurology Annual Meeting

Full release

SK Biopharmaceuticals and Arvelle Therapeutics Announce Agreement to Develop and Commercialize Cenobamate in Europe

Full release